In order to predict the synergistic effects of the HHT/ABT combination in AML with the NPM1 mutation to be translated into the clinics, we tested SiCoDEA with the OCI-AML3 cell line treated as described in the Section 2. This evidence concerns the gene NPM1 and acute myeloid leukemia.